Focused On-demand Library for Homeobox protein SIX3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O95343

UPID:

SIX3_HUMAN

Alternative names:

Sine oculis homeobox homolog 3

Alternative UPACC:

O95343; D6W5A5; Q53T42

Background:

Homeobox protein SIX3, also known as Sine oculis homeobox homolog 3, plays a pivotal role in brain and eye development. It acts as a transcriptional regulator, influencing the expression of genes critical for the formation of the forebrain, lens, and retina. SIX3 represses WNT1 to ensure proper brain patterning and activates SHH for ventral midline development. It also promotes ependymal cell maturation and neural progenitor cell differentiation through the regulation of CCND1 and CCND2.

Therapeutic significance:

SIX3's involvement in Holoprosencephaly 2 and Schizencephaly, conditions marked by brain structural anomalies, underscores its therapeutic potential. Understanding the role of Homeobox protein SIX3 could open doors to potential therapeutic strategies for these and related neurodevelopmental disorders.